Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.
Florian Sennlaub, Fatemeh Valamanesh, Alejandro Vazquez-Tello, Ahmed El-Asrar, Daniella Checchin, Sonia Brault, Fernand Gobeil, Martin Hervé Beauchamp, Bupe Mwaikambo, Yves Courtois, et al.

To cite this version:

HAL Id: inserm-00150824
http://www.hal.inserm.fr/inserm-00150824
Submitted on 15 Jan 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Cyclooxygenase-2 in Human and Experimental Ischemic Proliferative Retinopathy

F. Sennlaub, MD, PhD; F. Valamanesh, MSc; A. Vazquez-Tello, PhD; A.M. El-Asrar, MD, PhD; D. Checchin, MSc; S. Brault, MSc; F. Gobeil, PhD; M.H. Beauchamp, MSc; B. Mwaikambo, BSc; Y. Courtois, PhD; K. Geboes, MD, PhD; D.R. Varma, MD, PhD; P. Lachapelle, PhD; H. Ong, PhD; F. Behar-Cohen, MD, PhD; S. Chemtob, MD, PhD

Background—Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)–2 promotes tumor angiogenesis, we investigated the role of COX-2 in ischemic proliferative retinopathy.

Methods and Results—We describe here that COX-2 is induced in retinal astrocytes in human diabetic retinopathy, in the murine and rat model of ischemic proliferative retinopathy in vivo, and in hypoxic astrocytes in vitro. Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. COX-2 inhibition induced an upregulation of thrombospondin-1 and its CD36 receptor, consistent with the observed antiangiogenic effects of COX-2 inhibition; EP3 stimulation reversed effects of COX-2 inhibitors on thrombospondin-1 and CD36.

Conclusion—These findings point to an important role for COX-2 in ischemic proliferative retinopathy, as in diabetes. (Circulation. 2003;108:198-204.)

Key Words: prostaglandins ■ diabetes mellitus ■ ischemia ■ vasculature

Intravitreal neovascularization, which characterizes diabetic retinopathy, retinopathy of prematurity, or retinal vein occlusion, is a major cause of blindness. Retinal ischemia is a common precursor to vitreal neovascularization in retinal diseases and is associated with a local inflammatory response in the ischemic retina. Early proinflammatory genes are expressed in ischemic disorders. We have recently shown that inducible NO synthase contributes to the development of intravitreal neovascularization and to retinal apoptosis and degeneration.

Cyclooxygenase (COX)-2 is also an immediate-early gene product of inflammation. Prostanoids are synthesized principally via activities of COX-1 and COX-2. COX-1 is mostly constitutive and is expressed in most tissues. COX-2 is induced by cytokines, mitogens, and endotoxins, accounting for elevated prostaglandin production during inflammation.

COX-2 can be expressed developmentally and on ischemic stimuli in retina. COX-2 exerts an angiogenic effects in tumors and in corneal neovascularization. It has also been shown that prostanoids, notably prostaglandin E2 (PGE2), stabilize the hypoxia-inducible factor and stimulate expression of basic regulators of angiogenesis, including vascular endothelial growth factor (VEGF) in tumor endothelium, resulting in endothelial cell proliferation. We hereby investigated the role of COX-2 in a nontumoral condition, namely ischemic proliferative retinopathy, using human retinal tissue and experimental proliferative ischemic retinopathy. Our findings disclose an important role for this immediate-early gene product in proliferative retinopathy mediated (at least in part) by PGE2 mostly via prostaglandin E receptor 3 (EP3) through a previously undescribed action involving thrombospondin-1 (TSP-1) and CD36.

Methods

Human Samples
The eyes from 7 postmortem humans with diabetes mellitus, 4 eyes from 4 postmortem humans with no history of diabetes or ocular disease, and the ipsilateral eye from 1 subject with ocular ischemic syndrome secondary to severe carotid artery obstruction (case 12) were obtained.
Subject Characteristics and Results of COX-2 Staining

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Sex</th>
<th>Type of DM</th>
<th>Duration of DM, y</th>
<th>Cause of Death</th>
<th>Death to Enucleation, h</th>
<th>COX-2 Expression in NFL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>52, M</td>
<td>IDDM</td>
<td>14</td>
<td>Coronary artery disease</td>
<td>14</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>68, M</td>
<td>NIDDM</td>
<td>15</td>
<td>Intestinal ischemia</td>
<td>6</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>75, F</td>
<td>NIDDM</td>
<td>14</td>
<td>Coronary artery disease</td>
<td>17</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>74, F</td>
<td>NIDDM</td>
<td>10</td>
<td>Chronic obstructive pulmonary disease</td>
<td>12</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>70, M</td>
<td>NIDDM</td>
<td>20</td>
<td>Renal failure</td>
<td>9</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>58, M</td>
<td>NIDDM</td>
<td>16</td>
<td>Intracranial bleeding</td>
<td>10</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>67, F</td>
<td>NIDDM</td>
<td>18</td>
<td>Coronary artery disease</td>
<td>21</td>
<td>+</td>
</tr>
<tr>
<td>Subjects without diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>37, F</td>
<td>...</td>
<td>...</td>
<td>Cardiogenic shock</td>
<td>12</td>
<td>−</td>
</tr>
<tr>
<td>9</td>
<td>52, M</td>
<td>...</td>
<td>...</td>
<td>Colorectal cancer</td>
<td>17</td>
<td>−</td>
</tr>
<tr>
<td>10</td>
<td>78, M</td>
<td>...</td>
<td>...</td>
<td>Chronic obstructive lung disease</td>
<td>17</td>
<td>−</td>
</tr>
<tr>
<td>11</td>
<td>41, M</td>
<td>...</td>
<td>...</td>
<td>Road traffic accident</td>
<td>15</td>
<td>−</td>
</tr>
<tr>
<td>12</td>
<td>41, M</td>
<td>...</td>
<td>...</td>
<td>Road traffic accident</td>
<td>17</td>
<td>+</td>
</tr>
</tbody>
</table>

DM indicates diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; NIDDM, non–insulin-dependent diabetes mellitus; NFL, nerve fiber layer; M, male; and F, female.

Animal Models of Ischemic Proliferative Retinopathy

All procedures were conducted in accordance with the Association for Research in Vision and Ophthalmology’s statement, The Use of Animals in Ophthalmic and Vision Research.

In the murine model, C57BL/6 mice at postnatal day (P) 7 were exposed, with their mothers, for 5 days to hyperoxic conditions (75% O₂), inducing vaso-obliteration of the central retinal vasculature. At P12, mice were returned to room air; extensive vitreal neovascularization was present in all mice, with the maximum effect observed on P17. Ischemic proliferative retinopathy was also reproduced in Sprague-Dawley rats exposed to 7 cycles of hyperoxia (80% O₂, 20.5 hours) and hypoxia (10% O₂, 0.5 hours) with a gradual return to 80% O₂ over 3 hours, from P1 to P7. Thereafter, rats were returned to room air, and neovascularization was evaluated at P12.

Mice and rats were anesthetized with an intraperitoneal injection of a ketamine (100 mg/kg) and xylazine (15 mg/kg) solution and intravitreally injected using glass capillaries (~60 gauge). Right eyes of mice were injected intravitreally at P13 and P15 with 0.5 μL of vehicle (50% polyethylene glycol [Sigma-Aldrich], 40% PBS, and 10% ethanol); 2, 10, or 50 μL/mL of specific COX-2 inhibitor o-(Acetoxycarbonyl)hept-2-ynyl sulfide (APHS) or 16,16-dimethyl-PGE₂ (Sigma-Aldrich), resulting in estimated effective vitreal concentrations of drugs (estimated total eye volume of 10 μL based on sphere volume and volume-to-weight ratio calculation) of 0.2, 1, and 5 μmol/L (APHS and SC-560) and 0.03 μmol/L (16,16-dimethyl-PGE₂). Eyes were enucleated at P17 and subjected to retinal histochemistry (n=8) and intravitreal neovascularization quantification (n=8) (see below). Rat pups (n=8 to 13/group) were injected in the right eye at P7 and P9 with either 1 μL of vehicle (NaCl 0.9%) or the selective COX-2 inhibitor etodolac 40 μmol/L (Sigma-Aldrich) with or without 16,16-dimethyl-PGE₂, 4 μmol/L (Cayman Chemicals), a specific EP₂ or EP₃ agonist, respectively, butaprost 400 μmol/L (Cayman Chemicals) or M&B28767 4 μmol/L (Rhone-Poulenc Rorer), to obtain estimated effective vitreal concentrations of drugs (estimated total eye volume of 40 μL) of 1 (etodolac), 0.1 (16,16-dimethyl-PGE₂), 10 (butaprost), and 0.1 (M&B28767) μmol/L; EP₂ and EP₃ receptor agonists were used because antagonists are not readily available. Rats were euthanized at P12 and retinas stained for endothelial cells and flat mounted (see below).

Immunohistochemistry

Human and murine eyes were fixed in 4% paraformaldehyde and embedded, sectioned (5 μm), and deparaffinized. Sections were stained using a heat-induced antigen retrieval and a 3-step avidin–biotin complex technique using avidin–alkaline phosphatase or avidin-FITC as previously described. Antibodies used were polyclonal COX-2 antibody (Biomol Laboratories and Cayman Chemical Co), monoclonal EP₂ antibody (generous donation by Exalpa Biologicals), monoclonal glial fibrillary acidic protein (GFAP) (Oncogene), and TRITC-conjugated lectin griffonia simplicifolia (Sigma-Aldrich).

Cell Culture

Given the need for sufficient tissue quantities, primary astrocyte and endothelial cell cultures were obtained for practical reasons from neonatal porcine retinas; cells from this species respond to a variety of stimuli implicated in ischemic retinopathies in the same manner as that of rodent tissues. Neonatal porcine retinal astrocytes were isolated as described for brain astrocytes. Cells of the third to fourth passages were used. Cultures were ~95% GFAP positive. Monolayers (80% confluent) of astrocytes were incubated at 37°C either under normoxic (95% air, 5% CO₂) or hypoxic conditions (2% O₂, 5% CO₂, 93% N₂) for 24 hours. Subsequently, the medium was changed and cells were incubated for 1 hour in the presence of APHS (1 μmol/L), etodolac (1 μmol/L), SC-560 (0.2 μmol/L), or etodolac (1 μmol/L) and SC-560 (0.2 μmol/L); drug concentrations used were equivalent to those estimated in vivo. PGE₂ concentrations were measured in the supernatant, and the cells were harvested for protein quantification and Western blot analysis. The pH of the medium was unchanged during 24-hour hypoxia. For endothelial cell culture, newborn porcine neuroretinal microvessels were isolated as previously reported.

Western Blot

Protein extraction of cells was performed as previously described. Rat retinas were pooled and membranous and cytosolic fractions were separated as previously described. Antibodies used were polyclonal anti–COX-2 (Cayman); polyclonal anti–COX-1 (Santa Cruz Biotechnology); mouse monoclonal EP₂, EP₃, and EP₄ (Exalpa Biologicals); polyclonal anti–VEGF antibody (Chemicon); rat monoclonal anti–VEGF receptor (VEGFR)–2 (Chemicon); monoclonal anti–TSP-1 (Oncogene); polyclonal purified anti-CD36; monoclonal

Subject Characteristics and Results of COX-2 Staining

Table

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Sex</th>
<th>Age, y</th>
<th>Type of DM</th>
<th>Duration of DM, y</th>
<th>Cause of Death</th>
<th>Death to Enucleation, h</th>
<th>COX-2 Expression in NFL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>52, M</td>
<td>IDDM</td>
<td>14</td>
<td>Coronary artery disease</td>
<td>14</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>68, M</td>
<td>NIDDM</td>
<td>15</td>
<td>Intestinal ischemia</td>
<td>6</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>75, F</td>
<td>NIDDM</td>
<td>14</td>
<td>Coronary artery disease</td>
<td>17</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>74, F</td>
<td>NIDDM</td>
<td>10</td>
<td>Chronic obstructive pulmonary disease</td>
<td>12</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>70, M</td>
<td>NIDDM</td>
<td>20</td>
<td>Renal failure</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>58, M</td>
<td>NIDDM</td>
<td>16</td>
<td>Intracranial bleeding</td>
<td>10</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>67, F</td>
<td>NIDDM</td>
<td>18</td>
<td>Coronary artery disease</td>
<td>21</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Subjects without diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>37, F</td>
<td>...</td>
<td>...</td>
<td>Cardiogenic shock</td>
<td>12</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>52, M</td>
<td>...</td>
<td>...</td>
<td>Colorectal cancer</td>
<td>17</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>78, M</td>
<td>...</td>
<td>...</td>
<td>Chronic obstructive lung disease</td>
<td>17</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>41, M</td>
<td>...</td>
<td>...</td>
<td>Road traffic accident</td>
<td>15</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>41, M</td>
<td>...</td>
<td>...</td>
<td>Road traffic accident</td>
<td>17</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

DM indicates diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; NIDDM, non–insulin-dependent diabetes mellitus; NFL, nerve fiber layer; M, male; and F, female.
anti-clathrin (Transduction Laboratories, BD Biosciences); monoclonal anti–β-actin (Novus Biological); and monoclonal GFAP (Onco-gene). Western blots were performed on equal amounts of proteins as described.18

**PGE2 Radioimmunoassay**

PGE2 concentrations in retinal tissue (n=3 per group) and astrocyte supernatant were determined as previously described.22

**RNA Isolation and Reverse Transcription–Polymerase Chain Reaction (PCR) Analysis**

Retinal mRNA expression from whole retinal extracts (n=3 per group) was analyzed using reverse transcription–PCR (cycles below the saturating conditions) as previously described.4 Oligonucleotide primers were the following: for COX-2, antisense 5′-GGAGAAGGCTTCCCAGCTTTG-3′, and sense 5′-GCATAATTGCTGGTTCACC-3′, resulting in a PCR product of 336 bp; for actin, antisense 5′-GGTGGGTATGGGT-3′, and sense 5′-GGTGGGTATGGGT-CAGAAGGA-3′, resulting in a 630-bp PCR product.

**Quantification of Vitreal Neovascularization and Intraretinal Revascularization**

Mouse eyes were paraffin embedded, cut sagitally (parallel to the optic nerve), and stained with periodic acid-Schiff and Hemalun. Vitreal neovascularization (vascular cell nuclei found on the vitreal side of the inner limiting membrane) was counted by blinded investigators as previously described.3 Neovascular nuclei were absent in animals raised in room air. Intraretinal vasculature was visualized on retinal flat mounts stained with TRITC-conjugated lectin griffonia simplicifolia (Sigma-Aldrich),23 and the surface of the capillary free area measured using a computerized image-analy-sis system (Scion Image). In the rat model, intravitreal neovascularization was evaluated by counting intravitreal neovascular tufts on lectin-stained retinal flat mounts.

**Statistical Analysis**

Results are expressed as mean±SEM. Statistical analyses were performed using the Mann-Whitney test and ANOVA. Statistical significance was set at P<0.05.

**Results**

**COX-2 Expression in Human Diabetic Retina**

Patient characteristics are summarized in the Table. COX-2 immunoreactivity was observed in all eyes in the retinal pigment epithelial cells, in the outer segment of the photoreceptors and to some degree in the inner plexiform layer (data not shown). In all diabetic subjects, COX-2 immunoreactivity was also detected in the nerve fiber layer (NFL) (Figure 1a, cases 1 to 7); this COX-2 immunostaining was granular and discontinuous. COX-2 immunolocalized mostly with GFAP positive) (Figure 3e and 3f). In the post–hyperoxia-exposed retinas, COX-2 expression was also detected in the NFL at P14 (Figure 3a) predominantly in astrocytes (GFAP positive) (Figure 3e and 3f).

COX-2 expression was observed in room air and after hyperoxia exposure at P12, P14, and P17 (Figure 2A). Immunolocalization of COX-2 was studied in mouse retina and was found to be similar to that in humans. In normoxic mice at P14, COX-2 protein was robustly expressed in retinal pigment epithelial cells both in the outer photoreceptor segment and in the inner plexiform layer (data not shown). In the post–hyperoxia-exposed retinas, COX-2 expression was also detected in the NFL at P14 (Figure 2A) predominantly in astrocytes (GFAP positive) (Figure 3e and 3f).

COX-2 protein expression was evaluated in membrane fractions of retina extracts from hyperoxia-exposed rats. At the end of the hyperoxic period (P1 through P7), COX-2 immunoreactivity diminished and tended to increase in the early hours after resuming exposure to room air (24 hours after hyperoxia; Figure 2C). COX-1 exhibited the reverse pattern, and consequently whole retina concentrations of PGE2, a mediator involved in angiogenesis,25 were unaltered during the posthyperoxia period (Figure 2B); although this does not exclude a local paracrine effect of this autacoid. Consistent with these observations, primary retinal astrocyte cultures exposed for 24 hours to relative hypoxia (2% O2, 5% CO2, 93%) exhibited increased COX-2 expression (Figure 2D) and PGE2 levels (Figure 2E) compared with those in normoxia (95% air, 5% CO2), whereas COX-1 expression remained steady. Specific COX-2 inhibitors, APHS and etodolac, markedly dimin-
ished PGE\(_2\) levels, whereas COX-1–selective SC-560 only caused a small decrease in PGE\(_2\) concentrations (Figure 2E) even at highest dose tested (5 \(\mu\)mol/L), suggesting a dominant role for COX-2 in PGE\(_2\) generation during hypoxia.

In age-adjusted normoxic whole retinas, COX-1 and -2 expression did not change. Immunolocalization of COX-2 in rat retina was similar to that observed in mouse (data not shown).

**COX Inhibition in Ischemic Proliferative Retinopathy**

The impact of COX inhibition on neovascularization was tested using specific COX-2 (APHS and etodolac) and COX-1 (SC-560) inhibitors; concentrations corresponded to effective ones on astrocyte PGE\(_2\) levels (Figure 2E). In vivo, posthyperoxia administration of the preferential COX-2 inhibitor APHS did not affect the degree of capillary-free area or the intraretinal revascularization of the ischemic retina studied 4 days after the first dose (P17) (Figure 4A and 4B). However, intravitreal neovascularization (revealed by intravitreal vascular nuclear counts) was dose-dependently diminished by APHS, whereas the selective COX-1 inhibitor SC-560\(^{15}\) was ineffective (Figure 4C). PGE\(_2\) levels in whole retina were reduced by 65% 24 hours after APHS treatment. Moreover, intravitreal injection of PGE\(_2\) after the hyperoxic period led to a significant (albeit mild) increase in intravitreal neovascularization.

To confirm the role of COX-2 in retinal neovascularization, its involvement was tested using a distinct selective COX-2 inhibitor, etodolac,\(^{16}\) as well as a different species, the rat model of ischemic proliferative retinopathy. Etodolac caused a marked decrease in retinal neovascularization (studied at 5 days after the first injection) (Figure 5A and 5B). This effect was reversed by PGE\(_2\).

To further explore the PGE\(_2\) pathway, PGE\(_2\) receptor expression and its changes during the posthyperoxia period were studied. Hyperoxia caused a slight decrease in EP\(_1\) (Figure 5C), whereas EP\(_1\) was undetectable (not shown). In contrast, EP\(_2\) and to a greater extent EP\(_3\) receptor expression was significantly decreased by hyperoxia and increased substantially during the posthyperoxia period (Figure 5C), coincidental with COX-2 changes (Figure 2C). Moreover, addition of the EP\(_2\) agonist butaprost and the EP\(_3\) agonist M&B28767\(^{17}\) reversed in part or exacerbated the inhibitory effects of etodolac on retinal neovascularization. EP\(_3\) receptor expression also increased in the same phase in that of the murine eye, predominantly localized in retinal endothelium (lectin griffonia–positive cells) (Figure 3f through 3h).
Effects of COX-2 Inhibition and EP3 Stimulation on Expression of Modulators of Angiogenesis

Involvement of COX-2 and EP3 on pro- and antiangiogenic factors, notably VEGF, VEGFR2, TSP-1, and CD36,26,27 was studied in retina of models of proliferative retinopathy. Twenty-four hours after removal from hyperoxia, there was an increase in TSP-1 expression. The COX-2 inhibitor etodolac induced a substantial increase in both TSP-1 and CD36, and addition of the EP3 agonist M&B28767 reversed this effect. In contrast, effects of COX-2 on neovascularization could not be explained by the VEGF pathway; VEGF expression, although as anticipated it increased during the posthyperoxic period, was marginally affected by etodolac and M&B28767 (Figure 6A), and VEGFR2 remained unaltered. In accord with in vivo observations, etodolac caused a slight increase in TSP-1 expression in neuroretinovascular endothelial cells, and this effect was reversed by M&B28767 (Figure 6B), consistent with EP3 expression on retinal endothelium (Figure 3f).

Discussion

Inflammatory mediators contribute to the pathogenesis of ischemic proliferative retinopathy. In a related manner, COX-2 has been implicated in angiogenesis, especially of tumors. Although COX inhibition diminishes retinal neovascularization in ischemic models, the specific involvement of COX-2 and the identity of its products in this process have not been elucidated. Our findings disclose an important role for this immediate-early gene product in proliferative retinopathy. COX-2 expression increased coincidentally with that of EP2 and EP3 during the ischemic (posthyperoxic in models) phase associated with proliferation, particularly localized, respectively, in astrocytes and in endothelial cells of the NFL. COX-2 contributed to the preretinal neovascularization in different models of ischemic retinopathies, which seems to be mediated by PGE2 acting via EP2 and to a greater extent EP3 receptors, and these in turn modulate the antiangiogenic factor TSP-1 and its receptor CD36 on target endothelial cells.

COX-2 was abundantly present in synaptic regions of the retina of all species studied (human, mouse, and rat) as seen in the brain. In addition, COX-2 was induced in the NFL of retinas of humans with diabetes and vascular obstruction (case 12) and in animals after hyperoxia, hence during hypoxic-ischemic phases; in these instances, COX-2 was mostly induced in astrocytes (but also in endothelium [Figure
PGE2 generation during hypoxia (Figure 2E). Consistent with the time-dependent and propitious localization of COX-2, molecularly distinct inhibitors of this enzyme (APHS and etodolac15,16) markedly diminished preretinal neovascularization (Figures 4 and 5), whereas COX-1 inhibition was ineffective. Moreover, administration of the well-recognized proangiogenic COX product PGE22,5,10 (Figure 4) reversed the antiangiogenic effects of COX-1 and COX-2 inhibitors. Of note, we found augmented PGE2 generation during hypoxia (Figure 2E). Although a prostaglandin D2 metabolite–dependent peroxisome proliferator-activated receptor-γ-mediated induction of TSP-1 and CD36 has been documented35 an EP2-evoked one as we observed (Figure 6) discloses a previously undescribed mode of regulation of these antiangiogenic factors.

In summary, COX-2 contributes markedly to preretinal neovascularization in ischemic retinopathies, and this effect seems to be PGE2 mediated mostly via EP3 receptors implicating a new interaction through TSP-1 and CD36. Results suggest that selective COX-2 inhibitors could be used for the control of pathological vitreal neovascularization in ischemic proliferative retinopathy. More specifically, EP3 (and possibly EP2) antagonists may be more selective by sparing the potentially physiologically desirable effects of the various COX-2 products.

**Acknowledgments**

This work was supported by grants from the Canadian Institutes of Health Research, Fond de la Recherche en Santé du Québec (Réseau Vision), March of Dimes, and Heart and Stroke Foundation of Québec. Drs Sennlaub and Beauchamp are supported by fellowships from the Deutscher Akademischer Austauschdienst and the Canadian Institutes of Health Research, respectively. Dr Chemtob holds a Canada Research Chair. We thank Hendrika Fernandez for skillful technical assistance.

**References**

Regulation of angiogenesis by cyclooxygenase-2 inhibitors: insight into mechanisms and implications for cancer growth and ulcer healing.


